SEC Form 4 · accession 0001898490-26-000014
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rhonda Farnum
Officer — SVP, COMM & MEDICAL AFFAIRS
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 5:52 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Sep 15, 2026 | S | 3,329 | $17.0341 | D | 223,461 | D | |
| Ordinary SharesF1 | Sep 15, 2026 | S | 3,328 | $17.0343 | D | 220,133 | D | |
| Ordinary SharesF1 | Sep 15, 2026 | S | 6,657 | $17.0342 | D | 213,476 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices from $17.02 to $17.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
Remarks
These transactions were executed in accordance with the reporting person's 10b5-1 plan dated 09/03/2025.